Table 2.
Differences in the abundance of proteins in the plasma of patients by HL status (relapsed vs. non-relapsed) in the exploratory cohort (p < 0.05).
| UniProtKB ID | Gene | Protein | -LOG (p-Value) | Predicted Location * | Cancer/Disease-Related Gene | Tissue Protein Expression |
log2(FC) |
|---|---|---|---|---|---|---|---|
| More abundant in relapsed HL (n = 24) | |||||||
| P04264 | KRT1 | Keratin, type II cytoskeletal 1 | 3.94 | I | disease | ✓ | 1.59 |
| P35908 | KRT2 | Keratin, type II cytoskeletal 2 epidermal | 3.47 | I | disease | - | 1.58 |
| P01008 | SERPINC1 | Antithrombin-III | 3.41 | S | disease | ✓ | 1.49 |
| B9A064 | IGLL5 | Immunoglobulin λ-like polypeptide 5 | 1.91 | I, S | - | pending | 1.49 |
| P01871 | IGHM | Immunoglobulin heavy constant mu | 3.28 | I, M, S | disease | ✓ | 0.88 |
| Q08380 | LGALS3BP | Galectin-3-binding protein | 2.10 | S | cancer | ✓ | 0.88 |
| P01591 | JCHAIN | Immunoglobulin J chain | 3.41 | S | - | ✓ | 0.85 |
| P63261 | ACTG1 | Actin, cytoplasmic 2 | 2.88 | I | disease | ✓ | 0.85 |
| P02652 | APOA2 | Apolipoprotein A-II | 1.18 | I, S | cancer | - | 0.85 |
| Q9BXR6 | CFHR5 | Complement factor H-related protein 5 | 1.51 | S | disease | ✓ | 0.84 |
| P09871 | C1S | Complement C1s subcomponent | 3.73 | I, S | disease | - | 0.76 |
| P02679 | FGG | Fibrinogen γ chain ° | 1.28 | I, S | cancer | ✓ | 0.64 |
| P01876 | IGHA1 | Immunoglobulin heavy constant α 1 | 1.18 | I, M, S | disease | ✓ | 0.62 |
| P10909 | CLU | Clusterin ° | 1.79 | I, S | cancer | ✓ | 0.59 |
| P02788 | LTF | Lactotransferrin | 1.69 | I, S | cancer | ✓ | 0.57 |
| P04004 | VTN | Vitronectin ° | 2.27 | S | cancer | ✓ | 0.54 |
| P02649 | APOE | Apolipoprotein E ° | 1.34 | S | cancer | ✓ | 0.51 |
| P02741 | CRP | C-reactive protein | 3.63 | I, S | cancer | ✓ | 0.45 |
| O14791 | APOL1 | Apolipoprotein L1 | 1.12 | M, S | disease | ✓ | 0.39 |
| P00450 | CP | Ceruloplasmin | 1.66 | I, S | cancer | ✓ | 0.39 |
| P00734 | F2 | Prothrombin ° | 2.80 | I, S | cancer | ✓ | 0.34 |
| P02671 | FGA | Fibrinogen α chain | 1.22 | S | cancer | - | 0.33 |
| Q9HDC9 | APMAP | Adipocyte plasma membrane-associated protein | 1.19 | I, M | - | ✓ | 0.32 |
| P04003 | C4BPA | C4b-binding protein α chain ° | 1.31 | S | cancer | ✓ | 0.28 |
| More abundant in non-relapsed HL (n = 22) | |||||||
| P02647 | APOA1 | Apolipoprotein A-I | 1.69 | I, S | cancer | ✓ | −0.34 |
| P12259 | F5 | Coagulation factor V | 1.69 | S | disease | pending | −0.42 |
| P27169 | PON1 | Serum paraoxonase/arylesterase 1 | 1.32 | S | cancer | ✓ | −0.45 |
| P0C0L5 | C4B | Complement C4-B | 2.82 | I, S | disease | ✓ | −0.47 |
| P08603 | CFH | Complement factor H | 2.31 | S | cancer/disease | ✓ | −0.48 |
| P01624 | IGKV3-15 | Immunoglobulin kappa variable 3–15 | 2.55 | S | - | ✓ | −0.49 |
| P19823 | ITIH2 | Inter-α-trypsin inhibitor heavy chain H2 | 1.63 | S | - | ✓ | −0.50 |
| P07996 | THBS1 | Thrombospondin-1 | 2.36 | S | cancer | ✓ | −0.50 |
| P01619 | IGKV3-20 | Immunoglobulin kappa variable 3–20 | 1.39 | S | - | - | −0.52 |
| P0DJI9 | SAA2 | Serum amyloid A-2 protein | 1.22 | S | disease | pending | −0.54 |
| P01717 | IGLV3-25 | Immunoglobulin λ variable 3–25 | 1.76 | S | - | ✓ | −0.63 |
| P00747 | PLG | Plasminogen | 2.00 | S | cancer/disease | ✓ | −0.66 |
| P01857 | IGHG1 | Immunoglobulin heavy constant γ 1 | 1.74 | I, M, S | disease | ✓ | −0.68 |
| P06727 | APOA4 | Apolipoprotein A-IV | 1.87 | S | - | ✓ | −0.74 |
| P02746 | C1QB | Complement C1q subcomponent subunit B | 1.97 | S | disease | - | −0.85 |
| P02787 | TF | Serotransferrin | 3.42 | I, S | cancer/disease | ✓ | −0.89 |
| P01859 | IGHG2 | Immunoglobulin heavy constant γ 2 | 2.01 | I, M, S | - | ✓ | −0.96 |
| P01009 | SERPINA1 | α-1-antitrypsin | 3.93 | I, S | cancer | ✓ | −1.03 |
| P00738 | HP | Haptoglobin | 2.76 | I, S | cancer | ✓ | −1.12 |
| P02765 | AHSG | α-2-HS-glycoprotein | 2.54 | S | cancer/disease | ✓ | −1.23 |
| P01023 | A2M | α-2-macroglobulin | 2.89 | S | cancer | ✓ | −1.38 |
| P01700 | IGLV1-47 | Immunoglobulin λ variable 1–47 | 2.83 | S | - | pending | −1.42 |
° Difference in protein abundance confirmed in the validation cohort (Table S2); FC: fold change (LFQ intensity ratio between relapsed and non-relapsed HL). * generated after searching the Human Protein Atlas (www.proteinatlas.org; accessed on 2 February 2022): I, intracellular; M, membrane; S, secreted.